Enliven Therapeutics will present data from the ENABLE Phase 1 trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) Annual Meeting in Houston from September 9-12, 2026. The presentations, an oral session and a poster, are an encore of data previously presented at the European Hematology Association (EHA) 2026 Congress. ENABLE is evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML), including those with or without T315I mutations whose disease is relapsed, refractory or intolerant to tyrosine kinase inhibitors (TKIs). The dose-escalation and expansion study is designed to assess safety and tolerability and establish a recommended dose for further clinical evaluation. Enliven describes ELVN-001 as a selective, active-site inhibitor of BCR::ABL1, the cancer-driving protein produced by the BCR::ABL gene fusion, with activity designed to include the T315I mutation and mutations associated with resistance to allosteric BCR::ABL1 inhibitors. The company cautioned that statements about the drug's potential profile, clinical results, development plans and future regulatory or commercial prospects are forward-looking and subject to substantial risks and uncertainties.